Dr. Richard Aplenc is a Professor of Pediatrics in the Department of Pediatrics and the leader of the Aplenc Lab at CHOP. Dr. Aplenc’s research in the Aplenc Lab centers on pediatric acute myeloid leukemia (AML) with ongoing translational, patient-centered outcomes research, and large data projects aimed at improving treatment options and clinical outcomes for children with AML.

The Aplenc Lab has ongoing studies aimed at identifying new therapy targets and development of CAR trials for patients with AML. In addition, the Aplenc Lab has ongoing patient-centered outcome research studies. These focus on a multi-center study of inpatient versus outpatient management after administration of AML chemotherapy. This study integrates medical outcomes with semi-structured interviews and quality of life survey data. Finally, the Aplenc lab has multiple ongoing clinical epidemiology research studies utilizing and integrating multiple datasets. These include analysis of clinical trial data from Children’s Oncology Group (COG) Phase III trials, analyses of electronic medical record data from four leading pediatric institutions, analyses of administrative/billing data from the Pediatric Health Information Systems (PHIS), Medicare data, registry data from the Center for International Blood and Marrow Transplant Research (CIBMTR), and several projects merging these data sets.